KDM6B and acute myeloid leukemia: In addition, we show that H3.1 K27M AML cells are not more sensitive to drugs targeting other epigenetic regulators such as inhibitors against the histone demethylase JMJD3 (GSK-J4), BRD4 (JQ1) and histone deacetylases (vorinostat, trichostatin A and panobinostat) (Supplementary Fig. 7).